Drug Trial Radar · NCT06419374
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
May 24, 2024
Primary completion
Jun 30, 2028
Study completion Aug 31, 2031
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- May 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will assess the efficacy and safety of pegozafermin administered in participants with biopsy-confirmed and clinically confirmed compensated cirrhosis due to MASH .
Conditions
- Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
PegozaferminBiological
Subcutaneous injection
PlaceboDrug
Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants Achieving Fibrosis RegressionTime frame: Baseline through Month 24
- Time to First Occurrence of Disease Progression as Measured by Composite of Protocol -Specified Clinical EventsTime frame: Baseline up to 5 years
Locations
335 sites in 25 countries. Site status is shown where the registry gives one.
89bio Clinical Study Site
Birmingham, Alabama · Recruiting
89bio Clinical Study Site
Homewood, Alabama · Recruiting
89bio Clinical Study Site
Chandler, Arizona · Recruiting
89bio Clinical Study Site
Flagstaff, Arizona · Withdrawn
89bio Clinical Study Site
Peoria, Arizona · Recruiting
89bio Clinical Study Site
Phoenix, Arizona · Recruiting
89bio Clinical Study Site
Sun City, Arizona · Recruiting
89bio Clinical Study Site
Tucson, Arizona · Recruiting
89bio Clinical Study Site
Tucson, Arizona · Recruiting
89bio Clinical Study Site
Tucson, Arizona · Recruiting
89bio Clinical Study Site
Little Rock, Arkansas · Recruiting
89bio Clinical Study Site
North Little Rock, Arkansas · Recruiting
89bio Clinical Study Site
Camarillo, California · Recruiting
89bio Clinical Study Site
Canoga Park, California · Recruiting
89bio Clinical Study Site
Coronado, California · Recruiting
89bio Clinical Study Site
Fountain Valley, California · Recruiting
89bio Clinical Study Site
Fresno, California · Recruiting
89bio Clinical Study Site
Huntington Park, California · Withdrawn
89bio Clinical Study Site
La Jolla, California · Recruiting
89bio Clinical Study Site
Los Angeles, California · Recruiting
89bio Clinical Study Site
Los Angeles, California · Recruiting
89bio Clinical Study Site
Pasadena, California · Recruiting
89bio Clinical Study Site
Poway, California · Withdrawn
89bio Clinical Study Site
Redwood City, California · Recruiting
89bio Clinical Study Site
Rialto, California · Recruiting
89bio Clinical Study Site
Sacramento, California · Recruiting
89bio Clinical Study Site
Santa Ana, California · Withdrawn
89bio Clinical Study Site
Littleton, Colorado · Recruiting
89bio Clinical Study Site
Clermont, Florida · Recruiting
89bio Clinical Study Site
Fort Myers, Florida · Recruiting
89bio Clinical Study Site
Gainesville, Florida · Recruiting
89bio Clinical Study Site
Hialeah Gardens, Florida · Recruiting
89bio Clinical Study Site
Homestead, Florida · Recruiting
89bio Clinical Study Site
Jacksonville, Florida · Recruiting
89bio Clinical Study Site
Jacksonville, Florida · Recruiting
89bio Clinical Study Site
Lady Lake, Florida · Withdrawn
89bio Clinical Study Site
Lakewood Rch, Florida · Recruiting
89bio Clinical Study Site
Lehigh Acres, Florida · Recruiting
89bio Clinical Study Site
Maitland, Florida · Withdrawn
89bio Clinical Study Site
Miami, Florida · Recruiting
Showing 40 of 335 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.